Influence of folate pathway polymorphisms on high-dose methotrexate-related toxicity and survival in childhood acute lymphoblastic leukemia

References

• Jazbec J, Rajic V, Karas Kuzelicki N. Leukemias of childhood. Zdrav Vestn 2008;77:25–30.
   Google Scholar
• Conter V, Arico M, Basso G, . Long-term results of the Italian Association of Pediatric Hematology and Oncology (AIEOP) Studies 82, 87, 88, 91 and 95 for childhood acute lymphoblastic leukemia. Leukemia 2010;24:255–264.
   PubMed Web of Science ®Google Scholar
• Evans WE, Relling MV, Rodman JH, . Conventional compared with individualized chemotherapy for childhood acute lymphoblastic leukemia. N Engl J Med 1998;338:499–505.
   PubMed Web of Science ®Google Scholar
• Schmiegelow K. Advances in individual prediction of methotrexate toxicity: a review. Br J Haematol 2009;146:489–503.
   PubMed Web of Science ®Google Scholar
• Aplenc R, Lange B. Pharmacogenetic determinants of outcome in acute lymphoblastic leukaemia. Br J Haematol 2004;125:421–434.
   PubMed Web of Science ®Google Scholar
• Calvert H. An overview of folate metabolism: features relevant to the action and toxicities of antifolate anticancer agents. Semin Oncol 1999;26:3–10.
   PubMed Web of Science ®Google Scholar
• Hol FA, van der Put NM, Geurds MP, . Molecular genetic analysis of the gene encoding the trifunctional enzyme MTHFD (methylenetetrahydrofolate-dehydrogenase, methenyltetrahydrofolate-cyclohydrolase, formyltetrahydrofolate synthetase) in patients with neural tube defects. Clin Genet 1998;53:119–125.
   PubMed Web of Science ®Google Scholar
• Christensen KE, Rohlicek CV, Andelfinger GU, . The MTHFD1 p.Arg653Gln variant alters enzyme function and increases risk for congenital heart defects. Hum Mutat 2009;30:212–220.
   PubMed Web of Science ®Google Scholar
• Krajinovic M, Lemieux-Blanchard E, Chiasson S, . Role of polymorphisms in MTHFR and MTHFD1 genes in the outcome of childhood acute lymphoblastic leukemia. Pharmacogenomics J 2004;4:66–72.
   PubMed Web of Science ®Google Scholar
• Frosst P, Blom HJ, Milos R, . A candidate genetic risk factor for vascular disease: a common mutation in methylenetetrahydrofolate reductase. Nat Genet 1995;10:111–113.
   PubMed Web of Science ®Google Scholar
• Weisberg I, Tran P, Christensen B, . A second genetic polymorphism in methylenetetrahydrofolate reductase (MTHFR) associated with decreased enzyme activity. Mol Genet Metab 1998;64:169–172.
   PubMed Web of Science ®Google Scholar
• Rocha JC, Cheng C, Liu W, . Pharmacogenetics of outcome in children with acute lymphoblastic leukemia. Blood 2005;105: 4752–4758.
   PubMed Web of Science ®Google Scholar
• Aplenc R, Thompson J, Han P, . Methylenetetrahydrofolate reductase polymorphisms and therapy response in pediatric acute lymphoblastic leukemia. Cancer Res 2005;65:2482–2487.
   PubMed Web of Science ®Google Scholar
• Faganel Kotnik B, Grabnar I, Bohanec Grabar P, . Association of genetic polymorphism in the folate metabolic pathway with methotrexate pharmacokinetics and toxicity in childhood acute lymphoblastic leukaemia and malignant lymphoma. Eur J Clin Pharmacol 2011;67:993–1006.
   PubMed Web of Science ®Google Scholar
• Rots MG, Willey JC, Jansen G, . mRNA expression levels of methotrexate resistance-related proteins in childhood leukemia as determined by a standardized competitive template-based RT-PCR method. Leukemia 2000;14:2166–2175.
   PubMed Web of Science ®Google Scholar
• Horie N, Aiba H, Oguro K, . Functional analysis and DNA polymorphism of the tandemly repeated sequences in the 5’-terminal regulatory region of the human gene for thymidylate synthase. Cell Struct Funct 1995;20:191–197.
   PubMed Web of Science ®Google Scholar
• Mandola MV, Stoehlmacher J, Muller-Weeks S, . A novel single nucleotide polymorphism within the 5’ tandem repeat polymorphism of the thymidylate synthase gene abolishes USF-1 binding and alters transcriptional activity. Cancer Res 2003;63:2898–2904.
   PubMed Web of Science ®Google Scholar
• Kawakami K, Watanabe G. Identification and functional analysis of single nucleotide polymorphism in the tandem repeat sequence of thymidylate synthase gene. Cancer Res 2003;63:6004–6007.
   PubMed Web of Science ®Google Scholar
• Morganti M, Ciantelli M, Giglioni B, . Relationships between promoter polymorphisms in the thymidylate synthase gene and mRNA levels in colorectal cancers. Eur J Cancer 2005;41:2176–2183.
   PubMed Web of Science ®Google Scholar
• Pietrzyk JJ, Bik-Multanowski M, Skoczen S, . Polymorphism of the thymidylate synthase gene and risk of relapse in childhood ALL. Leuk Res 2011;35:1464–1466.
   PubMed Web of Science ®Google Scholar
• Krajinovic M, Costea I, Chiasson S. Polymorphism of the thymidylate synthase gene and outcome of acute lymphoblastic leukaemia. Lancet 2002;359:1033–1034.
   PubMed Web of Science ®Google Scholar
• Relling MV, Yang W, Das S, . Pharmacogenetic risk factors for osteonecrosis of the hip among children with leukemia. J Clin Oncol 2004;22:3930–3936.
   PubMed Web of Science ®Google Scholar
• Ravindranath Y. Down syndrome and leukemia: new insights into the epidemiology, pathogenesis, and treatment. Pediatr Blood Cancer 2005;44:1–7.
   PubMed Web of Science ®Google Scholar
• Schrappe M, Reiter A, Ludwig WD, . Improved outcome in childhood acute lymphoblastic leukemia despite reduced use of anthracyclines and cranial radiotherapy: results of trial ALL-BFM 90. German-Austrian-Swiss ALL-BFM Study Group. Blood 2000;95: 3310–3322.
   PubMed Web of Science ®Google Scholar
• Moricke A, Reiter A, Zimmermann M, . Risk-adjusted therapy of acute lymphoblastic leukemia can decrease treatment burden and improve survival: treatment results of 2169 unselected pediatric and adolescent patients enrolled in the trial ALL-BFM 95. Blood 2008; 111:4477–4489.
   PubMed Web of Science ®Google Scholar
• ALL IC-BFM 2002-Trial Steering Committee. A randomized trial of the I-BFM-SG for management of childhood non-B acute lymphoblastic leukemia. 2002. Available from http://kdho.if2.cuni.cz/docs/ALL_IC-Committees.pdf, accessed on 1.12.2011.
   Google Scholar
• Nathan DG, Orkin SH. Nathan and Oski's hematology of infancy and childhood. Boston: WB Saunders Company; 1998.
   Google Scholar
• Siberry GK, Iannone R. The Harriet Lane handbook: a manual for pediatric house officers. St. Louis: Mosby; 2000.
   Google Scholar
• Miller SA, Dykes DD, Polesky HF. A simple salting out procedure for extracting DNA from human nucleated cells. Nucleic Acids Res 1988;16:1215.
   PubMed Web of Science ®Google Scholar
• Jazbec J, Aplenc R, Dolzan V, . GST polymorphisms and occurrence of second neoplasms after treatment of childhood leukemia. Leukemia 2003;17:2540–2542.
   PubMed Web of Science ®Google Scholar
• Grabar PB, Rojko S, Logar D, . Genetic determinants of methotrexate treatment in rheumatoid arthritis patients: a study of polymorphisms in the adenosine pathway. Ann Rheum Dis 2010;69:931–932.
   PubMed Web of Science ®Google Scholar
• Bohanec Grabar P, Logar D, Lestan B, . Genetic determinants of methotrexate toxicity in rheumatoid arthritis patients: a study of polymorphisms affecting methotrexate transport and folate metabolism. Eur J Clin Pharmacol 2008;64:1057–1068.
   PubMed Web of Science ®Google Scholar
• Uchida K, Hayashi K, Kawakami K, . Loss of heterozygosity at the thymidylate synthase (TS) locus on chromosome 18 affects tumor response and survival in individuals heterozygous for a 28-bp polymorphism in the TS gene. Clin Cancer Res 2004;10:433–439.
   PubMed Web of Science ®Google Scholar
• Cortina-Borja M, Smith AD, Combarros O, . The synergy factor: a statistic to measure interactions in complex diseases. BMC Res Notes 2009;2:105.
   PubMedGoogle Scholar
• Leung W, Campana D, Yang J, . High success rate of hematopoietic cell transplantation regardless of donor source in children with very high-risk leukemia. Blood 2011;118:223–230.
   PubMed Web of Science ®Google Scholar
• Krajinovic M, Costea I, Primeau M, . Combining several polymorphisms of thymidylate synthase gene for pharmacogenetic analysis. Pharmacogenomics J 2005;5:374–380.
   PubMed Web of Science ®Google Scholar
• Petra BG, Janez J, Vita D. Gene-gene interactions in the folate metabolic pathway influence the risk for acute lymphoblastic leukemia in children. Leuk Lymphoma 2007;48:786–792.
   PubMed Web of Science ®Google Scholar
• Faganel Kotnik B, Grabnar I, Bohanec Grabar P, . Association of genetic polymorphism in the folate metabolic pathway with methotrexate pharmacokinetics and toxicity in childhood acute lymphoblastic leukaemia and malignant lymphoma. Eur J Clin Pharmacol 2011;67:993–1006.
   PubMed Web of Science ®Google Scholar
• Buitenkamp TD, Mathot RA, de Haas V, . Methotrexate-induced side effects are not due to differences in pharmacokinetics in children with Down syndrome and acute lymphoblastic leukemia. Haematologica 2010;95:1106–1113.
   PubMed Web of Science ®Google Scholar
• Joerger M, Huitema AD, Krahenbuhl S, . Methotrexate area under the curve is an important outcome predictor in patients with primary CNS lymphoma: a pharmacokinetic-pharmacodynamic analysis from the IELSG no. 20 trial. Br J Cancer 2010;102:673–677.
   PubMed Web of Science ®Google Scholar
• Wall AM, Gajjar A, Link A, . Individualized methotrexate dosing in children with relapsed acute lymphoblastic leukemia. Leukemia 2000;14:221–225.
   PubMed Web of Science ®Google Scholar
• Huang L, Tissing WJ, de Jonge R, . Polymorphisms in folate-related genes: association with side effects of high-dose methotrexate in childhood acute lymphoblastic leukemia. Leukemia 2008;22: 1798–1800.
   PubMed Web of Science ®Google Scholar
• Liu SG, Li ZG, Cui L, . Effects of methylenetetrahydrofolate reductase gene polymorphisms on toxicities during consolidation therapy in pediatric acute lymphoblastic leukemia in a Chinese population. Leuk Lymphoma 2011;52:1030–1040.
   PubMed Web of Science ®Google Scholar
• Speletas M, Papadopoulos N, Daiou C, . Relationship between 5,10-methylenetetrahydrofolate reductase C677T gene polymorphism and methotrexate related toxicity in patients with autoimmune diseases receiving folic acid supplementation. Ann Rheum Dis 2005;64: 1791–1792.
   PubMed Web of Science ®Google Scholar
• Shimasaki N, Mori T, Samejima H, . Effects of methylenetetrahydrofolate reductase and reduced folate carrier 1 polymorphisms on high-dose methotrexate-induced toxicities in children with acute lymphoblastic leukemia or lymphoma. J Pediatr Hematol Oncol 2006;28:64–68.
   PubMed Web of Science ®Google Scholar
• Kishi S, Cheng C, French D, . Ancestry and pharmacogenetics of antileukemic drug toxicity. Blood 2007;109:4151–4157.
   PubMed Web of Science ®Google Scholar
• Marcuello E, Altes A, del Rio E, . Single nucleotide polymorphism in the 5’ tandem repeat sequences of thymidylate synthase gene predicts for response to fluorouracil-based chemotherapy in advanced colorectal cancer patients. Int J Cancer 2004;112:733–737.
   PubMed Web of Science ®Google Scholar
• Bunni M, Doig MT, Donato H, . Role of methylenetetrahydrofolate depletion in methotrexate-mediated intracellular thymidylate synthesis inhibition in cultured L1210 cells. Cancer Res 1988;48:3398–3404.
   PubMed Web of Science ®Google Scholar
• van Ede AE, Laan RF, Blom HJ, . The C677T mutation in the methylenetetrahydrofolate reductase gene: a genetic risk factor for methotrexate-related elevation of liver enzymes in rheumatoid arthritis patients. Arthritis Rheum 2001;44:2525–2530.
   PubMed Web of Science ®Google Scholar
• Lauten M, Asgedom G, Welte K, . Thymidylate synthase gene polymorphism and its association with relapse in childhood B-cell precursor acute lymphoblastic leukemia. Haematologica 2003;88: 353–354.
   PubMed Web of Science ®Google Scholar
• Vidan-Jeras B, Jurca B, Dolzan V, . Slovenian Caucasian normal. In: Terasaki PI, Gjerston DW, editors. HLA 1998. Lenexa: American Society for Histocompatibility and Immunogenetics; 1998. pp. 180–181.
   Google Scholar